Biomea Fusion (BMEA) to Release Earnings on Monday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is expected to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Stock Performance

BMEA traded down $0.21 during trading on Thursday, hitting $1.95. 663,139 shares of the stock were exchanged, compared to its average volume of 913,793. The firm has a 50 day simple moving average of $3.14 and a 200 day simple moving average of $5.86. The firm has a market cap of $70.67 million, a price-to-earnings ratio of -0.49 and a beta of -0.26. Biomea Fusion has a 1 year low of $1.87 and a 1 year high of $14.43.

Analyst Ratings Changes

Several brokerages have recently commented on BMEA. Oppenheimer set a $10.00 price objective on Biomea Fusion in a report on Monday, March 24th. Barclays cut their price target on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Wednesday. D. Boral Capital reaffirmed a "buy" rating and set a $16.00 target price on shares of Biomea Fusion in a report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Biomea Fusion in a report on Monday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Biomea Fusion has a consensus rating of "Buy" and an average target price of $23.91.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.